Azitra Raises $3.75M in Series A

Inc, Azitra , announced today that the company has closed down $2. 9 million Series A venture round led by Bios Partners, bringing the total amount of outside funding to $3. $75 million Azitra is a preclinical biotechnology company that aims to treat skin conditions by using the skin’s own microbiome to create innovative, cost-effective and sustainable treatments for skin diseases ranging from eczema to staph infections. Previous seed funding sources include Peter Thiel’s Breakout Labs program to support advanced science and technology start-ups and other non-dilution grants.

Azitra’s leading proprietary candidate, “AZT-01,” is a recombinant strain of a safe skin bacterium that secretes therapeutic proteins locally into the skin. These bacteria, when applied to the skin using cream, will colonize the skin and restore the microbiome while treating the skin with therapeutic proteins. The funding will allow Azitra to continue testing its platform through a variety of skin conditions such as eczema, rare genetic skin diseases and cosmetic applications.

“The current approach of addressing disease symptoms alone is ineffective, and the microbiome is a nascent field of groundbreaking science with enormous potential,” said Azitra co-founder Travis Whitfill. “That’s why we’ve been passionate about starting a commercial organization that takes advantage of the power of the skin’s own microbiome to develop a new type of dermatology treatment. Such treatments are potentially safer, more targeted, and work better with fewer side effects than is currently available for often intractable conditions. “That’s right.

“Bios Partners is excited to invest in cutting-edge technology in the microbiome market, and we believe that Azitra has the capacity to be a paradigm shift in how skin disorders are treated,” said Dr. Aaron Fletcher, Managing Partner of Bios Partners “Azitra is taking the microbiome market to a new level of patient care not only by exploiting the advantages of a proper skin microbiome, but also by providing a delivery mechanism for missing proteins of various skin disorders. “That’s right.

The human body maintains nearly ten times as many microbial cells as human cells, according to the NIH Human Microbiome Project, and scientists are just beginning to exploit their potential.

“Many of the things that we put on the skin will intentionally or unintentionally interfere with its normal ecology,” said Dr. Lionard M Milstone, Senior Research Scientist in Dermatology at Yale University, and Azitra Consultant. “Developing therapies that make use of normal skin ecology is sensible and innovative. “That’s right.

Azitra About

Inc, Azitra It is a preclinical company that aims to harness the power of the microbiome on the skin. Since 2014, the company has worked with world-leading scientists in dermatology, microbiology and microbiomics to improve and test its platform. Visit www for more information. Azitrain Come on,

About Bios Partner

Bios Partners is a venture capital company focused on investing in early-stage biopharmaceutical and medical device companies. Founded in 2014 and based in Fort Worth, TX, the firm uses an experienced team of industry professionals to actively collaborate with its investment portfolio companies and enhance the value of its stakeholders. Investments in Azitra, Inc. One of the seven new investments made through the recently closed Bios Fund I

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Azitra/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co